Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2019.101909
Abstract: OBJECTIVE This meta-analysis investigated the effectiveness of PARP inhibitors (PARPis) as maintenance treatment in platinum sensitive recurrent ovarian cancer (ROC), stratifying results based on BRCA mutational status into five different categories: whole population, germ-line BRCA… read more here.
Keywords: maintenance treatment; brca mutational; analysis; treatment platinum ... See more keywords
NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-90361-w
Abstract: Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the… read more here.
Keywords: status; brca mutational; grade serous; serous advanced ... See more keywords
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Ovarian Research"
DOI: 10.1186/s13048-019-0484-6
Abstract: Epithelial ovarian cancer is the most lethal gynecologic malignancy. In most women, it is diagnosed at an advanced stage, which largely explains the poor prognosis of this malignancy. Germline mutations of the genes BRCA1 and… read more here.
Keywords: brca mutational; epithelial ovarian; high grade; treatment ... See more keywords